Objective: To determine the oncologic and complication outcomes of treatment of localised prostate cancer by High Intensity Focussed Ultrasound (HIFU) for primary treatment of prostate cancer in a whole of population, multi-user series.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Patients and Methods: We created a centralised database-accessible only by non-urologist researchers-within a cancer epidemiology centre, after ethics approval from that institution. A single researcher prospectively entered baseline, treatment and clinical/biochemical follow-up data from all patients managed with HIFU in the state of Victoria over the study period.
Results: We accrued 108 patients, of whom 103 had been staged as having clinically localised disease. Ninety-three patients (86.1%) had low or intermediate risk prostate cancer. Forty-four patients (40.5%) had persistent mild urinary incontinence at 3 months after treatment, and three of these ultimately underwent further surgical procedures to correct incontinence. Twenty-seven patients (25%) additionally experienced occasions of urinary retention in the first 3 months after treatment due to passage of tissue. Twenty-nine patients had achieved a PSA level of < 0.2 ng/mL at 3 months after HIFU. Fifty-six patients underwent post HIFU prostate biopsy and this was positive for residual cancer in 51 cases. Forty-five of the patients who had a positive post-HIFU biopsy underwent secondary treatment for prostate cancer.
Conclusion: Oncologic control and complication outcomes in this cohort were inferior to those previously reported for HIFU in single-user series. Given the population-based multi-user nature of our series we believe our observations are more likely to reflect the community outcomes that might be expected from widespread adoption of HIFU than generalising from single-operator series.
Bolton D, Ong K, Giles G, Lawrentschuk N, Severi G, Papa NP, Troy A, Woo HH, Millar J, Royce P. Are you the author?
University of Melbourne, Urology, 5/210 Burgundy street, Heidelberg, Melbourne, Victoria, Australia.
Reference: J Endourol. 2015 Jan 26. Epub ahead of print.